New Age Alpha Advisors LLC Has $3.19 Million Stock Position in United Therapeutics Corporation $UTHR

New Age Alpha Advisors LLC reduced its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 29.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,545 shares of the biotechnology company’s stock after selling 2,673 shares during the quarter. New Age Alpha Advisors LLC’s holdings in United Therapeutics were worth $3,189,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in UTHR. Darwin Global Management Ltd. acquired a new position in shares of United Therapeutics in the third quarter worth approximately $317,617,000. Baillie Gifford & Co. acquired a new position in shares of United Therapeutics in the fourth quarter worth approximately $157,390,000. Balyasny Asset Management L.P. lifted its stake in shares of United Therapeutics by 863.9% in the second quarter. Balyasny Asset Management L.P. now owns 152,727 shares of the biotechnology company’s stock worth $43,886,000 after acquiring an additional 136,883 shares during the period. Sofinnova Investments Inc. acquired a new position in shares of United Therapeutics in the second quarter worth approximately $34,055,000. Finally, Orbimed Advisors LLC acquired a new position in shares of United Therapeutics in the third quarter worth approximately $48,167,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently commented on UTHR. Royal Bank Of Canada cut their price objective on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Cantor Fitzgerald lifted their price objective on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Raymond James Financial began coverage on United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective on the stock. Oppenheimer lifted their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Finally, TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Thursday. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $619.42.

Insiders Place Their Bets

In other United Therapeutics news, Director Nilda Mesa sold 258 shares of United Therapeutics stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $581.93, for a total value of $150,137.94. Following the completion of the sale, the director directly owned 5,028 shares in the company, valued at approximately $2,925,944.04. The trade was a 4.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $565.98, for a total value of $5,376,810.00. Following the completion of the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $22,929,547.74. The trade was a 19.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 555,473 shares of company stock valued at $310,786,074. Company insiders own 8.60% of the company’s stock.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $568.43 on Tuesday. The company has a market cap of $24.13 billion, a P/E ratio of 20.98, a PEG ratio of 1.84 and a beta of 0.60. The stock has a 50 day simple moving average of $563.97 and a two-hundred day simple moving average of $513.01. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $6.63 earnings per share. On average, research analysts predict that United Therapeutics Corporation will post 27.07 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.